REG - ReNeuron Group plc - Total Voting Rights <Origin Href="QuoteRef">RQE.L</Origin>

ReNeuronAnnouncement

06/11/2015 15:32

RNS Number : 9159E
ReNeuron Group plc
06 November 2015
6 November 2015
AIM: RENE
ReNeuron Group plc
("ReNeuron" or "the Company")
Total Voting Rights
In conformity with the FCA's Disclosure and Transparency Rules, ReNeuron Group plc confirms that, as at the close of business on 30 October 2015, the Company had 3,159,256,868 ordinary shares of 1p each in issue, all with voting rights. The Company holds no ordinary shares in treasury. The above figure (3,159,256,868) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
Enquiries:
ReNeuron
+44 (0) 1483 302560
Olav Helleb , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan
+44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson
Cenkos Securities
+44 (0) 20 7397 8900
Stephen Keys, Dr Christopher Golden (NOMAD and Broker)
Russell Kerr (Sales)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for the blindness-causing disease, retinitis pigmentosa, is about to enter the clinic in the US. 
ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting a range of cancers.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
TVRZMMGMKVRGKZM